Portal de investigação
Modelling Propofol pharmacokinetics and pharmacodynamics during an intravenous anaesthesia guided by the bispectral index (Bis)
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2021
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
In vitro and in vivo anti-epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2-related self-limited epilepsy
Monni, L; (...); Fidzinski, P
Article. 10.1111/bph.15689. 2022
Absorption, metabolism and excretion of opicapone in human healthy volunteers
Loureiro, AI; (...); Soares-da-Silva, P
Article. 10.1111/bcp.15383. 2022
ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
ADOPTION Study: Status Update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor
Chavarria, D; (...); Borges, M.
Article. 10.1016/j.ejmech.2022.114740. 2022
Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives
Pinto, M; (...); Borges, F
Article. 10.1021/acsptsci.4c00124. 2024
Design of a double-blind, randomized, phase II trial in the prevention of epilepsy in stroke: anti-epileptogenic effects of eslicarbazepine acetate
Koepp, Matthias; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2021
Dopamine-beta-hydroxylase Short Interfering Nucleic Acid Overcomes the Short-term Efficacy of Timolol and Bimatoprost in Noradrenergic Overactivated Glaucomatous Eye
Carneiro, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2023
Drug-Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady-State Conditions in Healthy Subjects
Fonseca, Marlene; (...); Soares-da-Silva, Patricio
Article. 10.1002/jcph.2486. 2024
Drug-drug interaction study between zamicastat and furosemide in healthy subjects
Santos, Ana; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1183/13993003.congress-2021.PA1930. 2021
Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)
Cosme, D., Soares-da-Silva, P., Magro, F.
Correction. 10.1152/ajpgi.00139.2023_COR. 2023
Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells
Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando
Article. 10.1152/ajpgi.00139.2022. 2022
Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects
Fonseca, M; (...); Soares-da-Silva, P
Article. 10.1111/bcp.16167. 2024
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119432. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119439. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-b inhibitors and dopamine agonists: The real-world OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119433. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study
Pavese, N.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: Findings from the real-world OPTIPARK study
Pavese, Nicola; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119427. 2021
Effects of Opicapone on Sleep in Patients with Parkinson's Disease and Motor Fluctuations
Hauser, R.; (...); Klepitskaya, O.
Meeting Abstract. 2021
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations
Ebersbach, Georg; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119446. 2021
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
Antonini, Angelo; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119450. 2021
Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations
Lewitt, Peter; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119445. 2021
Gene silencing of LAT1 and ASCT2 Transporters via Short Interfering Nucleic Acid Therapies upon Human Colon Cancer HCT-116 Cell Xenografts
Carneiro, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2023
Impact of 3-month earlier versus later initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations
Carroll, Camille; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119447. 2021
Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations
Carroll, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10-2474
Cerqueira, Nuno M. F. S. A.; (...); Palma, P. Nuno
Article. 10.1002/cbic.202200166. 2022
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Mohamed, B.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Mohamed, Biju; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119431. 2021
Influence of disease duration on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Warnecke, Tobias; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119440. 2021
Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Carrolla, Camille; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119426. 2021
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119425. 2021
Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease Patients with Motor Fluctuations
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells
Cosme, D, soares-da-silva, p, Magro, F
Article. 10.1152/ajpcell.00208.2022. 2023
Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson's disease patients with motor fluctuations and reporting troublesome dyskinesia
Stocchi, Fabrizio; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119442. 2021
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
Loureiro, I, Ana; (...); Soares-da-Silva, Patricio
Article. 10.1002/prp2.891. 2022
Metabolism and disposition of zamicastat in rats.
Araújo F; (...); Loureiro AI
Article. 10.1080/00498254.2024.2411993. 2024
OCEAN Study in Parkinson's Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone
Chaudhuri, K.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Off-Time and Sleep in Patients with Parkinson's Disease and Motor Fluctuations
Hauser, Robert A.; (...); Klepitskaya, Olga
Meeting Abstract. 2021
Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone analysis of health economic costs in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study
Lees, Andrew; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119441. 2021
Opicapone in clinical practice in Parkinson's disease German patients with motor fluctuations: Findings from the OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119429. 2021
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: Findings from the OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119451. 2021
Opicapone in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study
Lees, Andrew; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119428. 2021
Opicapone in German Parkinson's disease patients with motor fluctuations: Results on WOQ-9, QoL and non-motor symptoms.
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Opicapone in Parkinson's Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations
Reichmann, H; (...); Soares-da-Silva, P
Article. 10.1159/000523771. 2022
Over-blending effect of lubricants on capsules manufacturing: a simple and fast wettability technique to predict batch dissolution performance
Barrocas, P.; (...); Vasconcelos, T.
Article. 10.1080/10837450.2023.2196332. 2023
Overcoming short term efficacy of timolol an bimatoprost in noradrenergic overactivated glaucomatous eye with chemically modified short interference nucleic acids targeting dopamine-beta-hydroxylase
Carneiro, Catarina; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2023
PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF P-GLYCOPROTEIN TRANSPORTER INHIBITION MEDIATED BY CARVEDILOL ON THE PHARMACOKINETICS OF ZAMICASTAT
Magalhaes, Luis; (...); Soares-da-Silva, Patricio
Meeting Abstract. 10.1016/j.chest.2021.07.2015. 2021
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone
Jenner, P; (...); Soares-da-Silva, P
Review. 10.1080/14737175.2021.1968298. 2021
Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
Magalhaes, LM; (...); Soares-da-Silva, P
Article. 10.1007/s40264-021-01097-5. 2021
Salt-inducible kinases: new players in pulmonary arterial hypertension?
Antonio, Tatiana; (...); Gomes, Pedro
Review. 10.1016/j.tips.2022.06.008. 2022
SLEEP PATTERNS AND ``OFF''-TIME IN PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS
Hauser, Robert; (...); Klepitskaya, Olga
Meeting Abstract. 2022
Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Status Update of EPSILON: a Phase III, Randomised, PlaceboControlled Study of Opicapone in Early Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients
Ferreira, Joaquim; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119438. 2021
Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson's Disease Patients
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The ADOPTION (eArly levoDopa with Opicapone in Parkinson's paTients wIth motOr fluctuatioNs) study in Parkinson's disease: design and rationale of a randomized prospective, open-label exploratory trial
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The design of a multicentre, double-blind, randomized, placebo-controlled, Phase II trial in the prevention of epilepsy in stroke patients at high risk of unprovoked seizures: Anti-epileptogenic effects of eslicarbazepine acetate
Koepp, M.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2022
The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson's disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The OASIS (OpicApone in Sleep dISorder) study in Parkinson's disease: design and rationale of an open-label, single-arm, pilot trial
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The oasis (opicapone in sleep disorder) study in Parkinson's disease: Design and rationale of an open-label, single-arm, pilot trial
Costa, Raquel; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119430. 2021
Voltage-clamp evidence of GABA(A) receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem
Fernandes, H; (...); Soares-da-Silva, P
Article. 10.1007/s43440-022-00411-x. 2022
